A Comparison of Intramuscular and Subcutaneous Administration of LigA Subunit Vaccine Adjuvanted with Neutral Liposomal Formulation Containing Monophosphoryl Lipid A and QS21

A Comparison of Intramuscular and Subcutaneous Administration of LigA Subunit Vaccine Adjuvanted with Neutral Liposomal Formulation Containing Monophosphoryl Lipid A and QS21

Leptospirosis vaccines with higher potency and reduced adverse effects are needed for human use. The carboxyl terminal domain of leptospiral immunoglobulin like protein A (LigAc) is currently the most promising candidate antigen for leptospirosis subunit vaccine. However, LigAc-based vaccines were u...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Teerasit Techawiwattanaboon, Christophe Barnier-Quer, Tanapat Palaga, Alain Jacquet, Nicolas Collin, Noppadon Sangjun, Pat Komanee, Kanitha Patarakul
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: MDPI AG 2020-09-01
Cyfres:Vaccines
Pynciau:
leptospirosis
<i>Leptospira</i>
LigA subunit vaccine
LMQ adjuvant
vaccination route
intramuscular
Mynediad Ar-lein:https://www.mdpi.com/2076-393X/8/3/494

Rhyngrwyd

https://www.mdpi.com/2076-393X/8/3/494

Eitemau Tebyg